Herriot Tabuteau, CEO of Axsome Therapeutics (AXSM), has demonstrated a consistent pattern of selling company shares over recent months, with no open-market purchases reported since at least late 2025. SEC filings reveal 12 sales between October 2025 and February 2026, totaling approximately $76.1 million in gross proceeds, dwarfing the $4.2 million in total buy value across all historical transactions. The disposals occurred in concentrated bursts, with particularly large sales on November 3, 2025 ($12.1 million), January 5, 2026 ($13.5 million), and February 2, 2026 ($6.0 million). Each sale was accompanied by smaller "M"-coded transactions, likely representing tax withholdings on equity awards.
The selling activity spans multiple quarters without interruption, suggesting a systematic reduction rather than isolated liquidity events. Notably, Tabuteau's February 26, 2026 filing showed an acquisition (code "A") with no reported value, typically indicating a grant of equity compensation rather than an open-market purchase. The absence of any recent buys, combined with the scale and frequency of sales—averaging roughly $6 million per transaction in the most active months—paints a clear disposition trend. All transactions relate exclusively to AXSM, where Tabuteau remains CEO, with no diversification into other securities evident in the filings. The pattern aligns with executives monetizing long-held positions, though the filings themselves disclose no strategic rationale for the disposals.
AI-assisted summary